Wuhan Hiteck Biological Pharma Co Ltd Net Assets
Wuhan Hiteck Biological Pharma Co Ltd net assets. Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has net assets worth CN¥2.09 Billion CNY (≈ $305.83 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.47 Billion ≈ $361.62 Million USD) and total liabilities (CN¥381.30 Million ≈ $55.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Wuhan Hiteck Biological Pharma Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.09 Billion |
| % of Total Assets | 84.57% |
| Annual Growth Rate | 19.55% |
| 5-Year Change | -7.41% |
| 10-Year Change | 208.44% |
| Growth Volatility | 44.87 |
Net Assets of Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
Net assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300683 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
The table below shows the annual net assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. For live market cap and overall valuation, see Wuhan Hiteck Biological Pharma Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.17 Billion ≈ $317.45 Million |
-10.04% |
| 2024-12-31 | CN¥2.41 Billion ≈ $352.89 Million |
-3.36% |
| 2023-12-31 | CN¥2.50 Billion ≈ $365.17 Million |
+6.87% |
| 2022-12-31 | CN¥2.34 Billion ≈ $341.71 Million |
-0.34% |
| 2021-12-31 | CN¥2.34 Billion ≈ $342.86 Million |
+35.83% |
| 2020-12-31 | CN¥1.72 Billion ≈ $252.41 Million |
-2.02% |
| 2019-12-31 | CN¥1.76 Billion ≈ $257.61 Million |
+2.98% |
| 2018-12-31 | CN¥1.71 Billion ≈ $250.17 Million |
+4.04% |
| 2017-12-31 | CN¥1.64 Billion ≈ $240.44 Million |
+133.61% |
| 2016-12-31 | CN¥703.35 Million ≈ $102.92 Million |
+17.86% |
| 2015-12-31 | CN¥596.76 Million ≈ $87.32 Million |
+11.21% |
| 2014-12-31 | CN¥536.59 Million ≈ $78.52 Million |
+110.72% |
| 2013-12-31 | CN¥254.64 Million ≈ $37.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Hiteck Biological Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Wuhan Hiteck Biological Pharma Co Ltd Net Assets Breakdown (December 2025)
Wuhan Hiteck Biological Pharma Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥138.83 Million | 6.43% |
| Other Components | CN¥2.02 Billion | 93.57% |
| Total Equity | CN¥2.16 Billion | 100.00% |
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Market Cap
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hansa Biopharma AB
ST:HNSA
|
$426.49 Million |
|
Testa Residencial SOCIMI S.A.
MC:YTST
|
$426.54 Million |
|
Keck Seng Malaysia Bhd
KLSE:3476
|
$426.69 Million |
|
Shoppers Stop Limited
NSE:SHOPERSTOP
|
$426.69 Million |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
$426.13 Million |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
$426.12 Million |
|
FinVolution Group
NYSE:FINV
|
$425.82 Million |
|
Ningbo Bird Co Ltd
SHG:600130
|
$425.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Hiteck Biological Pharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,391,790,341 to 2,160,524,623, a change of -231,265,718 (-9.7%).
- Net loss of 231,265,718 reduced equity.
- Dividend payments of 17,869,628 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-231.27 Million | -10.7% |
| Dividends Paid | CN¥17.87 Million | -0.83% |
| Other Changes | CN¥17.87 Million | +0.83% |
| Total Change | CN¥- | -9.67% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Hiteck Biological Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.64x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.94 | CN¥22.25 | x |
| 2014-12-31 | CN¥7.73 | CN¥22.25 | x |
| 2015-12-31 | CN¥7.78 | CN¥22.25 | x |
| 2016-12-31 | CN¥9.01 | CN¥22.25 | x |
| 2017-12-31 | CN¥18.96 | CN¥22.25 | x |
| 2018-12-31 | CN¥16.43 | CN¥22.25 | x |
| 2019-12-31 | CN¥16.96 | CN¥22.25 | x |
| 2020-12-31 | CN¥16.39 | CN¥22.25 | x |
| 2021-12-31 | CN¥21.85 | CN¥22.25 | x |
| 2022-12-31 | CN¥18.11 | CN¥22.25 | x |
| 2023-12-31 | CN¥19.07 | CN¥22.25 | x |
| 2024-12-31 | CN¥18.28 | CN¥22.25 | x |
| 2025-12-31 | CN¥16.51 | CN¥22.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Hiteck Biological Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.71%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.19x
- Recent ROE (-10.70%) is below the historical average (6.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 30.68% | 21.81% | 0.81x | 1.74x | CN¥52.34 Million |
| 2014 | 20.56% | 20.03% | 0.68x | 1.50x | CN¥56.46 Million |
| 2015 | 13.98% | 12.27% | 0.78x | 1.46x | CN¥23.74 Million |
| 2016 | 22.54% | 20.37% | 0.74x | 1.49x | CN¥87.37 Million |
| 2017 | 8.70% | 18.98% | 0.39x | 1.17x | CN¥-21.25 Million |
| 2018 | 5.54% | 15.93% | 0.27x | 1.27x | CN¥-75.82 Million |
| 2019 | 3.60% | 10.16% | 0.29x | 1.24x | CN¥-112.19 Million |
| 2020 | -1.46% | -4.77% | 0.24x | 1.28x | CN¥-195.89 Million |
| 2021 | 1.19% | 4.50% | 0.23x | 1.16x | CN¥-204.79 Million |
| 2022 | -0.61% | -2.04% | 0.25x | 1.17x | CN¥-245.07 Million |
| 2023 | -4.88% | -20.06% | 0.20x | 1.20x | CN¥-368.64 Million |
| 2024 | -2.90% | -10.69% | 0.22x | 1.23x | CN¥-308.53 Million |
| 2025 | -10.70% | -42.71% | 0.21x | 1.19x | CN¥-447.32 Million |
Industry Comparison
This section compares Wuhan Hiteck Biological Pharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,124,889,896
- Average return on equity (ROE) among peers: 7.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Hiteck Biological Pharma Co Ltd (300683) | CN¥2.09 Billion | 30.68% | 0.18x | $426.18 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $902.62 Million | 5.17% | 3.60x | $492.82 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $363.79 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $366.91 Million | 9.97% | 0.26x | $4.71 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.91 Billion | 13.83% | 0.64x | $2.63 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $14.36 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $766.98 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.54 Million | 1.60% | 1.47x | $273.68 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $889.22 Million | 5.34% | 2.43x | $935.44 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.04 Billion |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredi… Read more